Anixa Biosciences Inc. has reported final Phase 1 results for its investigational breast cancer vaccine targeting the α-lactalbumin protein, showing that the primary endpoints were met and 74 percent of participants demonstrated protocol-defined immune responses. The data were presented at the 2025 San Antonio Breast Cancer Symposium and build the case for a Phase 2 trial in newly diagnosed breast cancer patients, potentially in combination with pembrolizumab.

The investigational vaccine was found to be safe and well tolerated at the maximum tolerated dose. Importantly, when combined with pembrolizumab, the vaccine produced antigen-specific T cell responses without introducing major additional side effects. This outcome supports the transition into a planned Phase 2 neoadjuvant study, positioning the program within an emerging space of immunopreventive oncology interventions.

Why α-lactalbumin presents a novel angle in breast cancer vaccine development

Anixa Biosciences, in collaboration with Cleveland Clinic, is targeting α-lactalbumin, a protein normally present only during lactation but re-expressed in many forms of breast cancer, particularly triple-negative breast cancer. Unlike many tumor-associated antigens, α-lactalbumin is conditionally expressed and absent from other healthy tissues in non-lactating adults. This makes it an attractive target for immune intervention without the risk of triggering broad autoimmunity.

The strategy hinges on identifying “retired proteins”—proteins that are no longer needed under normal physiological conditions but re-emerge abnormally in malignancies. By targeting these proteins, the immune system can be selectively trained to eliminate emerging tumor cells without harming healthy tissue. The α-lactalbumin construct follows this logic and is rooted in foundational work led by the late Vincent Tuohy at Cleveland Clinic. The scientific proposition is that targeting a protein that should be immunologically silent in the adult body minimizes the risk of off-target toxicity.

This mechanism distinguishes the program from earlier-generation breast cancer vaccine efforts. Prior candidates frequently focused on proteins like HER2, MUC1, or survivin, which are either weakly immunogenic or too broadly expressed. These efforts struggled with immune tolerance, insufficient T cell activation, or unacceptable safety concerns. Anixa’s approach circumvents these issues by focusing on a narrow, time-locked antigen.

What does a 74 percent immune response rate actually mean in this context?

The trial’s topline result that 74 percent of participants exhibited protocol-defined immune responses suggests robust T cell engagement. According to the presentation, participants developed α-lactalbumin-specific T cells capable of producing cytokines such as interferon gamma and interleukin-17. This data was derived from peripheral blood analysis and supported by the absence of flu-like symptoms or abnormal laboratory markers.

However, industry observers note that while these results reflect successful immune priming, they are not direct surrogates for clinical efficacy. The trial did not measure tumor regression, recurrence delay, or survival endpoints. Instead, it was designed to evaluate whether the vaccine could safely induce an immune response against the target antigen.

That said, the 74 percent response rate places Anixa’s candidate among the more promising breast cancer vaccines in early development. Immune activation levels above 50 percent have historically been difficult to achieve in solid tumors, especially in prophylactic or adjuvant settings. The ability to do so without triggering significant toxicity is noteworthy, and it suggests that the vaccine formulation is potent enough to proceed into efficacy trials.

Why the pembrolizumab combination is a key inflection point

One of the three cohorts in the Phase 1 study focused specifically on evaluating the safety and immunogenicity of the vaccine when administered alongside pembrolizumab, a PD-1 checkpoint inhibitor marketed by Merck under the brand name Keytruda. This checkpoint inhibitor is already approved for triple-negative breast cancer in various treatment stages.

The combination arm, referred to as Cohort Ic, was designed to test whether checkpoint blockade would synergize with vaccine-induced immune priming without increasing the risk of adverse events. The trial found no dose-limiting toxicities or serious immune-related complications in this group. The main side effect continued to be injection-site irritation, with only two participants experiencing Grade 3 events.

From an immunological perspective, checkpoint inhibitors like pembrolizumab can remove the brakes on cytotoxic T cells once activated. If the vaccine provides the signal to prime T cells against α-lactalbumin, pembrolizumab may enhance the downstream cytotoxic effect. The absence of toxicity in the combination arm is an important validation point, indicating that a Phase 2 neoadjuvant trial with pembrolizumab is both safe and rational to pursue.

Regulators and clinicians alike will be watching whether the vaccine can deepen the immune response beyond that of checkpoint inhibitors alone, especially in tumors that lack pre-existing immune infiltration.

What stands out in the trial design and population selection

The Phase 1 trial enrolled 35 participants across three cohorts, representing a diverse but rational population structure for an early-stage immunization study. Cohort Ia included women who had completed standard-of-care treatment for early-stage triple-negative breast cancer within the prior three years. These individuals were tumor-free at the time of enrollment but remained at elevated risk of recurrence.

Cohort Ib enrolled cancer-free women with BRCA1, BRCA2, or PALB2 mutations who elected to undergo preventive mastectomy. In this group, the vaccine was administered prior to surgery, and immunohistochemistry analysis of the resected breast tissue is ongoing. This arm is particularly important as it explores the preventive potential of the vaccine, not just its use as an adjuvant therapy.

Cohort Ic focused on patients actively receiving pembrolizumab in the adjuvant setting, making it the first step toward combination-based treatment. The study’s ability to stratify safety and immune response across these groups adds analytical weight to the final dataset. It also builds a foundation for future trial designs targeting different clinical scenarios, including prevention, post-treatment surveillance, and neoadjuvant therapy.

How does this vaccine compare with other breast cancer immunization strategies?

The immunotherapy landscape for breast cancer remains relatively sparse compared to other tumor types. Vaccines against HER2 have struggled with immunogenicity and were often crowded out by the success of monoclonal antibodies like trastuzumab. Attempts to target telomerase, survivin, or MUC1 have seen inconsistent clinical progress.

In contrast, Anixa’s α-lactalbumin vaccine introduces a conceptually cleaner target with limited expression outside of lactation. This dramatically reduces concerns about immune tolerance or collateral tissue damage. It also opens the possibility of deploying the vaccine in healthy individuals with elevated genetic risk, much like HPV vaccines are used to prevent cervical cancer.

Clinicians tracking the field believe that Anixa’s approach may help shift the cancer vaccine narrative away from therapeutic salvage toward immunoprevention, especially if the Phase 2 trials can incorporate surrogate markers of long-term protection or early recurrence suppression.

What are the key scientific and regulatory unknowns moving into Phase 2?

The most immediate unknown is the correlation between immune response and clinical protection. While the Phase 1 data confirm immune engagement, it remains unclear whether this translates into reduced recurrence, improved progression-free survival, or true prevention in genetically predisposed populations.

The second unknown is antigen expression consistency. Preliminary immunohistochemistry analyses showed α-lactalbumin expression in tumors ranged from absent to strong. Future trial success may depend on the ability to pre-screen patients for sufficient target expression, which introduces operational complexity.

On the regulatory front, the pathway remains undefined. The vaccine may straddle categories between therapeutic biologic and preventive vaccine, each with its own evidentiary standards. A neoadjuvant trial measuring tumor infiltration, immune persistence, and long-term survival may offer the most pragmatic route to conditional approval. However, regulators will likely demand clear biomarker validation and data reproducibility across multiple patient populations.

Why the commercial and manufacturing challenges should not be underestimated

Even if clinical efficacy is confirmed, manufacturing scalability remains a key challenge. Cancer vaccines typically require rigorous formulation control, cold chain logistics, and repeat dosing protocols. Anixa will need to demonstrate that its vaccine can be manufactured under GMP standards at scale, with consistent batch performance and immunogenicity.

Commercial adoption will also depend on health-economic validation. Payers will want to see whether a vaccine that prevents recurrence or delays metastasis can reduce the cost burden of late-stage treatment. In high-cost subtypes like triple-negative breast cancer, where long-term surveillance and relapse therapies can be expensive, the vaccine could present a compelling value proposition. However, real-world uptake will hinge on clear cost-effectiveness modeling and strategic positioning in treatment guidelines.

What comes next and what stakeholders should watch for

Anixa Biosciences has indicated its intention to begin regulatory engagement and move forward with a Phase 2 study. This next stage will need to address not just immune response durability but also patient stratification based on antigen expression, predictive biomarkers, and potential synergy with checkpoint inhibitors.

Regulators, investors, and cancer centers will be watching to see whether Anixa can secure external partnerships or institutional collaborations to support larger trials. The company’s alliance with Cleveland Clinic offers a strong scientific base, but broader validation will require larger multicenter studies with real-world patient diversity.

As the immunoprevention category continues to evolve, the α-lactalbumin vaccine may represent a first-mover advantage in one of oncology’s most difficult frontiers: preventing cancer before it starts.

  alpha-lactalbumin, Anixa Biosciences, breast cancer vaccine, cancer prevention, cancer vaccine, checkpoint inhibitor, Cleveland Clinic, immunotherapy, pembrolizumab, triple-negative breast cancer